From: National Institutes of Health NIH-Funded Trial Results Likely Will Impact Global Treatment Guidelines A major international randomized clinical trial has found that HIV-infected individuals have a considerably lower risk of developing AIDS or other serious illnesses if they start taking antiretroviral drugs sooner, when their CD4+ T-cell count—a key measure of immune system health—is higher, Continue Reading
A new study sheds light on how to halve the number of new HIV infections among men who have sex with men in Bangkok.
This spring, in an effort to enhance national HIV prevention efforts, the Thai Red Cross AIDS Research Centre and Adam’s Love, Thailand’s leading Internet and social media-based HIV outreach initiative, are working on two groundbreaking endeavors to bring oral pre-exposure prophylaxis (PrEP) to MSM
Researchers involved with Adam’s Love, an Internet and social media-based HIV outreach initiative engaging men who have sex with men (MSM) in Thailand, published an article in the April edition of the Journal of Virus Eradication detailing the impact of its first four years of operation.
Access to antiretroviral therapy (ART) is increasing among the 3.4 million children living with HIV globally—though in many regions their rates of treatment access remain lower than adults. Because HIV-positive children face a lifetime of ART, adherence is critical to ensuring that they do not develop resistance, especially in countries where access to second- and third-line therapies remains limited.
In 2008, the Thai Red Cross AIDS Research Centre, a TREAT Asia network member in Bangkok, opened the Anonymous Clinic—a sexual health clinic with specific services for men who have sex with men (MSM). Because MSM living with HIV are twice as likely as those without HIV to develop the anal cancer associated with human papillomavirus (HPV), the clinic determined to start screening its patients for anal precancers.
HIV infection is rising in Australia. Find out about PrEP drug Truvada, which could prevent transmission.
HIV-positive people living in Thailand discuss what a cure would mean to them.
Dr. Jintanat Ananworanich, a TREAT Asia and amfAR investigator, is leading some of the most exciting adult and pediatric HIV cure research occurring in the world today. Her studies are investigating how and if getting patients on antiretroviral therapy (ART) as soon after infection as possible can
It is with profound sorrow that I have received the news that Professor Joep Lange, Founder and Co-Director of HIV-NAT within the Thai Red Cross AIDS Research Center, as well as the other 5 delegates, who were attending the 20th International AIDS Conference in Melbourne, passed away in the tragic crash of Malaysia Airlines MH17 in eastern part of Ukraine.
I wish to extend my heartfelt sympathy and condolences to you, and through you, to the bereaved families and all members of HIV-NAT for this irreparable loss of such the dedicated and leading figures in the AIDS research.